# US 2024/0199604 A1 · Supramolecular polymer therapeutics and diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199604 A1
- Document ID: US20240199604A1
- Status: Published application
- Kind: A1
- Application number: 18/468,633
- Filed: 2023-09-15
- Published: 2024-06-20
- Earliest claimed: 2022-09-15
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Stanley B. Prusiner; Nick A. Paras; Jay Conrad; Ny Sin; Sandeep Raikar; Mark Vander Wal; Jean-Marc M. Grandjean; Shigeo Yamanoi; Masahiro Inoue; Shimpei Hirano; Masatoshi Honzumi; Koji Sasaki; Yamato Suzuki; Atsushi Tengeiji; Daniel R. Southworth; Darren Hutt; Jacob I. Ayers; Steven H. Olson; Cuong Quoc Ly; John West; Gregory E. Merz; Helene Viart; Osamu Iwamoto
- Web page: https://patentgrep.com/patent/US20240199604A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 31/4245: Oxadiazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/497: containing further heterocyclic rings
- A61K 31/499: Spiro-condensed pyrazines or piperazines
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 495/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- G01N 2800/2821: Alzheimer
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention provides compounds, and methods of using those compounds to treat neurodegenerative diseases.

## Claims

### Claim 1

A compound, or a salt or a hydrate or a solvate thereof, having a structure according to formula (I):
wherein
T is substituted or unsubstituted naphthyridinone or substituted or unsubstituted dihydronaphthyridinone;
X is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, wherein X is monocyclic; and
Z is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted ethenyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, wherein T is
wherein Ra, Rb, Rc, and Rd are independently selected from H, halogen, substituted or unsubstituted C1-3 alkyl, C2-C4 alkenyl, substituted or unsubstituted C1-3 alkoxy, and when the connection between C* and C** is a single bond, Ra and Rb can be optionally joined with C* or with C** to form a substituted or unsubstituted cyclopropyl.

### Claim 3 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, wherein T is

### Claim 4 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, wherein T is

### Claim 5 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, wherein X is substituted or unsubstituted phenyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted thienyl.

### Claim 6 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, wherein X is 4-(trifluoromethyl)phenyl, 4-fluorophenyl, 2-(trifluoromethyl)pyridin-5-yl, or 2-(1,1-difluoroethyl)pyridin-5-yl.

### Claim 7 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, wherein Z is substituted or unsubstituted phenyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted furan, substituted or unsubstituted thienyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted oxazolyl.

### Claim 8 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, wherein Z is 1-methylisoquinolin-6-yl, 2-(trifluoromethyl)pyrimidin-4-yl, 2-methylpyrimidin-4-yl, 1-methyl-6-isoquinolyl, 1-(2-hydroxyethyl)-6-isoquinolyl, 3-isoquinolyl, 6-quinolyl, 8-fluoro-3-quinolyl, 8-fluoro-7-quinolyl, 4-methyl-1,7a-diaza-2-indenyl, 1-thia-5-aza-2-indenyl, 1-(2-fluoroethyl)-1H-indazol-5-yl, 3-quinolyl, 2-cyclopropyl-2H-indazol-5-yl, 6-fluoro-1,3-benzoxazol-2-yl, 5-fluoro-2-pyridyl, 1-benzofuran-2-yl, or phenyl.

### Claim 9 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, having a structure according to formula (II), (III), (IV), (V), (VI), (VII), (VIII), or (IX):

### Claim 10 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, which is 7-{5-[6-(1,1-difluoroethyl)-3-pyridyl]-2-(1-methyl-6-isoquinolyl)-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-{2-[1-(2-hydroxyethyl)-6-isoquinolyl]-5-[6-(trifluoromethyl)-3-pyridyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-{2-[1-(2-hydroxyethyl)-6-isoquinolyl]-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-[5-(p-fluorophenyl)-2-(3-isoquinolyl)-1,3-oxazol-4-yl]-1,7-diaza-8 (7H)-naphthalenone, 7-[5-(p-fluorophenyl)-2-(6-quinolyl)-1,3-oxazol-4-yl]-1,7-diaza-8 (7H)-naphthalenone, 7-{2-(8-fluoro-3-quinolyl)-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-[5-(p-fluorophenyl)-2-(8-fluoro-7-quinolyl)-1,3-oxazol-4-yl]-1,7-diaza-8 (7H)-naphthalenone, 7-{2-(4-methyl-1,7a-diaza-2-indenyl)-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-{2-(1-thia-5-aza-2-indenyl)-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-{2-[1-(2-fluoroethyl)-1H-indazol-5-yl]-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-{2-(3-quinolyl)-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-{2-(2-cyclopropyl-2H-indazol-5-yl)-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-{2-(6-fluoro-1,3-benzoxazol-2-yl)-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-{5-[p-(trifluoromethyl)phenyl]-2-[2-(trifluoromethyl)-4-pyrimidinyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-{2-(5-fluoro-2-pyridyl)-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone, 7-[2-(1-benzofuran-2-yl)-5-(p-fluorophenyl)-1,3-oxazol-4-yl]-1,7-diaza-8 (7H)-naphthalenone, or 7-{2-phenyl-5-[p-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-1,7-diaza-8 (7H)-naphthalenone.

### Claim 11 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, which is 7-(2-(2-methylpyrimidin-4-yl)-5-(4-(trifluoromethyl)phenyl)oxazol-4-yl)-6,7-dihydro-1,7-naphthyridin-8 (5H)-one.

### Claim 12 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, which is 7-(5-(4-(trifluoromethyl)phenyl)-2-(2-(trifluoromethyl)pyrimidin-4-yl)oxazol-4-yl)-1,7-naphthyridin-8 (7H)-one.

### Claim 13 (depends on 1)

The compound of claim 1, or a salt or a hydrate or a solvate thereof, which is 7-(2-(1-methylisoquinolin-6-yl)-5-(4-(trifluoromethyl)phenyl)oxazol-4-yl)-1,7-naphthyridin-8 (7H)-one.

### Claim 14

A compound of formula (XVI):
wherein:
R1, R5, and R6 are each independently selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkyl, substituted alkyl, —CH2R20, —CHMeR20, —CH(OH)R20, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, alkenyl, alkynyl, acyl, nitro, halo, amino, substituted amine, ether, thioether, and H;
Ar is selected from aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
A is selected from N, CH, C(halo);
X is selected from O and N—R2;
R2 and R20 are each independently selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, alkenyl, alkynyl, acyl, and H; and
Ring B is a 5-membered heteroaryl ring.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the compound has formula (XVII):

### Claim 16 (depends on 15)

The compound of claim 15, wherein the compound has formula (III):
wherein:
R7-9 each are independently selected from halogen, H, alkyl, substituted alkyl, alkoxy, substituted alkoxyl.

### Claim 17 (depends on 16)

The compound of claim 16, wherein the compound has formula (XIII)(a), (XIII)(b), (XIII)(c), (XIII)(d), (XIII)(e), or (XIII)(f):

### Claim 18 (depends on 16)

The compound of claim 16, wherein the compound has formula (XIV)(a) or (XIV)(b):
wherein:
Z9-Z13 are each independently selected from N and CRZ;
Z14-Z18 are each independently selected from N, O, S, and CRZ;
each RZ is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted alkyl, heterocycloalkyl, substituted heterocycloalkyl.

### Claim 19 (depends on 1)

A pharmaceutical formulation comprising:
a) the compound, or a pharmaceutically acceptable salt or a hydrate or a solvate thereof, of claim 1; and
b) a pharmaceutically acceptable excipient.

### Claim 20

A compound, or a salt or a hydrate or a solvate thereof, having a structure according to any of the structures in FIG. 6.
